Each week, The Fly will announce the newest downgrades to Strong Sell in StockNews.com's POWR Ratings algorithmic model.

This Fly exclusive recap identifies stocks with over a $1B market capitalization that have been downgraded this week to the Strong Sell, or "F," rating in the service's proprietary model that analyzes 118 different factors, each of which contribute a little to the stock's predicted likelihood of underperformance. A bell curve distribution of StockNews.com's ratings shows that only the top 5% of the over 5,000 stocks rated by the system are assigned a "Strong Buy," or "A," rating while the bottom 5% are assigned a Strong Sell. The F-rated stocks would have tumbled an average of 18.98% a year since 1999, according to StockNews.com.

This week's downgrades to Strong Sell as determined by the POWR Ratings algorithm: 

• XPeng (XPEV) - a Chinese electric vehicle company that designs, develops, manufactures, and markets Smart EVs
• Intellia Therapeutics (NTLA) - a clinical-stage genome editing company developing novel, potentially curative therapeutics leveraging CRISPR-based technologies
  
• GameStop (GME) - a video game retail store operator that brands itself as "a multi-brand network" whose goal is "to deliver games to our customers anytime, anywhere and on any device"
  
• PureCycle Technologies (PCT) - a U.S.-based company that holds a global license for a solvent-driven purification recycling technology designed to transform polypropylene plastic waste into a continuously renewable resource
  
• Sigma Lithium (SGML) - a Canadian company that is currently in construction at its wholly owned Grota do Cirilo Project in Brazil with a stated goal to "power the next generation of electric vehicle batteries with environmentally sustainable and high-purity lithium"
  
• Radius Global Infrastructure (RADI) - an owner and acquirer of real property interests and contractual rights underlying essential digital infrastructure assets in 21 countries
  
• AST SpaceMobile (ASTS) - a company building what it calls "the first and only global cellular broadband network in space to operate directly with standard, unmodified mobile devices"
  

Learn more about the POWR Ratings

The Fly's recent reporting on these stocks includes: 

On September 22, Morgan Stanley analyst Tim Hsaio wrote that the G9's starting price came in slightly higher than market expectations, but "investors in general reckon the price of G9 is not aggressive enough to upstage peers' models," after XPeng revealed the pricing and specifications for its fourth production model G9 Flagship SUV for the Chinese market. The analyst, who argues that a "lack of meaningful surprise" from the G9 launch together with the Fed's rate hike triggered a correction in XPeng's share price on September 21, thinks XPeng offered an "upbeat volume outlook" by stating that it expects G9 volume next year to exceed what it has achieved for the P7. Hsaio has an Overweight rating and $41 price target on XPeng shares.

The day prior, XPeng revealed the pricing and specifications for its G9 Flagship SUV for the Chinese market. "The G9 lineup includes three series - each with a different driving range - and six configurations in total. There will be three series of G9-each with a different driving range-and six configurations in total. These are the RWD 570G, RWD 570E, and RWD 702E; 4WD Performance 650E and 650X; and a Launch Edition 650X. The 4WD Performance models come with a dual-chamber air suspension system as standard. G9 will start from 309,900 up to 469,900 RMB with the first deliveries for customers in China expected in October," the company stated.

Also on September 21, JPMorgan analyst Brian Cheng initiated coverage of Intellia Therapeutics with an Overweight rating and $85 price target. The analyst also added Intellia to the firm's U.S. Analyst Focus List as a Growth idea. Intellia is a biotech company leading the way in deploying gene editing therapies to treat rare diseases and cancers, Cheng tells investors. The analyst thinks the company is "attractively positioned given its versatility and validation in clinics." The early clinical data from '2001 in transthyretin amyloidosis and '2002 in hereditary angioedema "provided strong proof of mechanism as first-in-class therapies," says the analyst. More importantly, the improvement in HAE attacks reported last week was the first confirmation in a relevant outcome measure, Cheng writes. He believes the "data-rich set of catalysts near-term" should continue to keep investors engaged in Intellia as its portfolio matures.

Taking the other side, Citi analyst David Lebowitz kept a Sell rating on Intellia Therapeutics after the company reported interim clinical data from Phase I/II studies for NTLA-2002 and NTLA-2001. Both therapies "show clear signs of activity, but also raise some questions," Lebowitz tells investors in a research note. He says that while NTLA-2002 contributes to kallikrein protein knockdown and a reduction in attacks, he awaits kallikrein activity data. On NTLA-2001, transthyretin knockdown suggests likely benefit on outcome-based endpoints for transthyretin amyloidosis, but safety and market opportunity "remain unclear," contends Lebowitz.